In fact, in the meta-analysis of Schrijver et al., there were 14-62% and 67% patients changed their treatment corresponding to HoR and HER2 discrepancy between primary and recurrent/metastatic tumors (7). The gene discussed is ERBB2; the disease is metastatic neoplasm.